Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00864773
NCT00864773UnknownNot Applicable

Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab

Hallym University Medical Center0 sites10 target enrollmentStarted: March 1, 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
10
Primary Endpoint
Concentrations of growth factors and inflammatory cytokines in Aqueous humor
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Investigator)

Eligibility Criteria

Ages
30 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with a diagnosis of central serous chorioretinopathy
  • •Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography
  • •Presence of focal leaks at the level of the RPE on fluorescein angiography

Exclusion Criteria

  • •Known side effects of systemic bevacizumab administration
  • •Have a significant cardiovascular or thromboembolic history or were pregnant

Outcomes

Primary Outcomes

Concentrations of growth factors and inflammatory cytokines in Aqueous humor

Time Frame: at baseline

Secondary Outcomes

  • Central macular thickness at optical coherence tomography(baseline, 1 month, 3 months, 6 months)

Investigators

Sponsor Class
Other

Similar Trials

Completed
Not Applicable
Central Serous Chorioretinopathy: Etiology, Course and PrognosisCentral Serous Chorioretinopathy
NCT01378130Medical University of Vienna50
Completed
Phase 2
Central Serous Retinopathy risk factors and efficacy of Dorzolamid dropCentral Serous Retinopathy.H35.71Central serous chorioretinopathy
IRCT20180703040323N1Birjand University of Medical Sciences60
Completed
Not Applicable
Investigation of the etiology of central serous chorioretinopathy using en face OCT and indocyanine green angiographyCentral Serous Chorioretinopathy
JPRN-UMIN000020640ihon University Hospital25
Recruiting
Not Applicable
Central Serous Chorioretinopathy and Micropulse Laser TreatmentCentral Serous Chorioretinopathy
NCT06346405Fondazione Policlinico Universitario Agostino Gemelli IRCCS36
Not yet recruiting
Not Applicable
Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous ChorioretinopathyCentral Serous Chorioretinopathy
NCT05687422Beijing Hospital50